IRAK-1-4 Inhibitor I,
509093-47-4,
IRAK-1/4 Inhibitor I,
IRAK-1/4 Inhibitor,
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor,
CHEMBL379787,
N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide,
N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole,
N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitrobenzamide,
IRAK-1-4InhibitorI,
IRAK1/4 Inhibitor I,
MLS006010636,
GTPL5990,
SCHEMBL3600534,
CTK8E9833,
DTXSID50475143,
QTCFYQHZJIIHBS-UHFFFAOYSA-N,
HMS3229G05,
HMS3263A20,
BCP16164,
EX-A1254,
KS-00001D4X,
Tox21_501049,
3747AH,
BDBM50184706,
IN1449,
MFCD09752602,
ZINC16052821,
AKOS026750497,
CCG-206760,
CS-0704,
LP01049,
NCGC00186035-01,
NCGC00186035-02,
NCGC00186035-03,
NCGC00186035-04,
NCGC00261734-01,
HY-13329,
SMR001456469,
RT-013346,
J3.545.430F,
A11462,
W-5402,
IRAK-1/4 Inhibitor I, >=98% (HPLC), solid,
1-(2-(4-Morpholinyl)ethyl)-2-(3-nitrobenzoylamino)benzimidazole,
1-[2-(4-Morpholinyl)ethyl]-2-(3-nitrobenzoylamino)-1H-benzoimidazole,
3-nitro-N-(1-(2-morpholin-4-yl-ethyl)-1H-benzoimidazol-2-yl)-benzamide,
Benzamide, N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitro-,
N-(1-(2-morpholinoethyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide,
N-{1-[2-(morpholin-4-yl)ethyl]-1H-1,3-benzodiazol-2-yl}-3-nitrobenzamide,
D0I2FZ,
C20H21N5O4,
CID11983295,
A3505,
N-[1-(2-morpholin-4-ylethyl)benzoimidazol-2-yl]-3-nitro-benzamide,